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Food allergies are adverse immune reactions to food proteins that affect up to 6% of children and 3-4% of adults. A wide range of symptoms can 
occur depending on whether IgE or non-IgE mediated mechanism are involved. Many factors influence the development of oral tolerance, 
including route of exposure, genetics, age of the host, and allergen factors. Advances have been made in the understanding of how these factors 
interact in the pathophysiology of food allergy. Currently, the mainstay of treatment for food allergies is avoidance and ready access to emergency 
medications. However, with the improved understanding of tolerance and advances in characterization of food allergens, several therapeutic 
strategies have been developed and are currently being investigated as potential treatments and/or cures for food allergy.
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INTRODUCTION
Food allergies are adverse immune reactions to food proteins 
that can range from immediate, potentially life-threatening re-
actions to chronic disorders such as atopic dermatitis and aller-
gic gastrointestinal disorders. While many studies have investi-
gated the prevalence of food allergies, few population studies 
have used the gold standard double-blind, placebo-controlled 
food challenges (DBPCFC) to confirm the diagnosis of food al-
lergy, which can lead to an overestimated prevalence. A meta-
analysis focusing on milk, egg, peanut, and seafood allergy 
found the prevalence of food allergies to be approximately 
3.5%.
1 The majority of the studies included in this meta-analysis 
used self-reports of food allergy, many utilized skin prick testing 
and food-specific IgE levels to confirm sensitization to the food 
allergens, and fewer employed DBPCFCs. The prevalence of 
food allergies has also been documented to have increased in 
the last 10-15 yrs, particularly in developed countries. Specifi-
cally, studies on peanut allergy in the US and UK indicate that 
the number of children affected has doubled, with the preva-
lence now over 1%.
2,3
The most common food allergens causing reactions in chil-
dren include milk, egg, wheat, soy, peanuts, tree nuts, fish and 
shellfish. While the majority of children outgrow their allergy to 
milk, egg, wheat and soy, allergies to peanut, tree nuts, fish and 
shellfish often persist into adulthood. The persistence of food 
allergy is variable, depending on the specific food allergen. Re-
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cent reports indicate that it is taking longer for children to out-
grow their milk and egg allergy, with most developing tolerance 
in their teenage years rather that in early school-age as previ-
ously thought.
4,5 In contrast, only 20% of children with peanut 
allergy and 9% with tree nut allergy will develop tolerance.
6,7
The key to management of food allergies consists of education 
about food allergen avoidance and the use of emergency medi-
cations (e.g., epinephrine) for the treatment of allergic reac-
tions. Although this approach is generally effective, avoidance 
can be very difficult since many common food allergens are 
ubiquitous in the diet.
8 Therefore, patients and their families of-
ten experience a significant negative impact on their quality of 
life.
9 Furthermore, food allergic reactions are potentially life-
threatening,
10-12 with peanuts and tree nuts accounting for 80% 
of food-induced fatal anaphylaxis cases. Severe reactions can 
occur both inside and outside of the home, and victims are of-
ten not aware that the products they were eating contained the 
food allergens.
This review will focus on the immunopathophysiology of food 
allergy and discusses therapeutic strategies currently being in-
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vestigated with the aim of long-term treatment and possible 
cure of food allergy. 
TYPES OF FOOD ALLERGY
Immune reactions to foods can be IgE-mediated, cell-mediat-
ed or result from a combination of IgE and non-IgE mecha-
nisms (Table 1). IgE-mediated reactions occur within 2 hrs of 
exposure. Binding of food allergens by specific IgE on effector 
cells, such as basophils and mast cells, leads to mediator release 
(i.e. histamine, tryptase, cysteinyl leukotrienes, prostaglandin 
D2) causing a variety of symptoms that typically affect the cuta-
neous, respiratory, gastrointestinal and/or cardiovascular sys-
tems. Serum IgE and prick skin testing measure allergen-spe-
cific IgE, and these provide an indication of the likelihood of 
allergic reaction with exposure to the food allergen, however 
the type of reactions that occur are unpredictable in severity. 
Predictive values for serum food-specific IgE levels and prick 
skin testing have been published for the major food allergens, 
and levels above the 95% positive predictive value are highly in-
dicative of clinical reactivity.
13-17 It has also been shown that the 
rate of decline in food specific IgE levels over time has predic-
tive value for the development of tolerance.
18 
Cell-mediated reactions to foods include food protein-in-
duced enterocolitis syndrome (FPIES) and proctocolitis. FPIES 
is characterized by repetitive vomiting and diarrhea at least 2 
hrs after ingestion of the food trigger, with common ones in-
cluding milk, soy and grains. Dehydration often occurs, with 
hypotension and metabolic acidosis ensuing in severe cases.
19 
The immediate treatment for symptoms includes intravenous 
fluid hydration. As in other food allergies, food avoidance is im-
portant. Periodic re-evaluation with physician-supervised oral 
food challenges are advised to determine whether the allergy 
has been outgrown. Food protein-induced proctocolitis is com-
monly triggered by cow’s milk and soy, and symptoms can be 
triggered by exposure through maternal breast milk. Infants are 
generally brought to medical attention for evaluation of blood 
streaked stools. These infants are otherwise well in terms of 
growth and do not generally suffer adverse effects from blood 
loss, such as anemia. Symptoms resolve with maternal and in-
fant avoidance of milk, and the majority of children outgrow 
this allergy by 1 yr of age.
20 
Atopic dermatitis and eosinophilic gastroenteropathies are 
triggered by a combination of IgE and cell-mediated processes. 
Approximately 35% of children with moderate-severe atopic 
dermatitis have food allergies as a trigger.
21 Removal of culprit 
foods results in significant improvement in skin symptoms for 
these children. In an international multicenter study of children 
with atopic dermatitis, a close association between early-onset, 
moderate-to-severe eczema and egg sensitization was found.
22 
Children who developed atopic dermatitis after 12 months of 
age were less likely to have concurrent food allergies. 
Table 1. Types of food allergy 
Disorder Mechanism Clinical features Immunopathology Common food triggers
Urticaria/angioedema, 
anaphylaxis
IgE Cutaneous, gastrointestinal,  
respiratory symptoms
Cross-linking of IgE results in release 
of mediators
Major allergens - Milk, egg, 
wheat, soy, peanut, tree nuts, 
fish and shellfish
Oral Allergy syndrome IgE Mild oropharyngeal symptoms 
primarily (pruritus, angioedema)
Primary sensitization to pollen 
proteins which are homologous to 
food proteins in certain fruits/
vegetables
Raw fruits and vegetables
Food-dependent, exercise-
induced anaphylaxis
IgE Food triggers anaphylaxis only if 
ingestion is followed by exercise
Enhanced mast cell releasability and 
altered intestinal permeability when 
food ingestion is followed by exercise
Wheat, shellfish and celery are 
the most commonly reported 
triggers
Atopic dermatitis Mixed IgE/
non-IgE
Chronic inflammatory skin disease, 
pruritic
IgE-mediated activation of cutaneous 
mast cells; late phase infiltration of 
inflammatory cells, including 
eosinophils and T cells
Egg, wheat, milk, soy, and 
others
Eosinophilic gastroenter-
opathies
Mixed IgE/
non-IgE
Dysphagia, poor growth, abdominal 
complaints (nausea, vomiting)
Eosinophilic infiltration of the 
gastrointestinal tract, mediators of 
eosinophils play a role (i.e. IL-5, 
eotaxin)
Multiple foods
Food-protein induced  
enterocolitis
Non-IgE Delayed emesis, diarrhea 2 hours 
following ingestion, severe cases 
– hypotension in 15% 
Increased TNFa, decreased TGFb Milk, soy, grains
Food-protein induced  
proctocolitis
Non-IgE Blood-streaked stools in infants Eosinophilic infiltration in the colon Milk and soy, can occur via 
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Allergic eosinophilic esophagitis (AEE) and allergic eosino-
philic gastroenteritis (AEG) are inflammatory disorders charac-
terized by high numbers of intraepithelial eosinophils in the 
gastrointestinal tract.
23-25 Although the etiology is still unclear, 
many patients have IgE-mediated food and aeroallergen sensi-
tization. In a series of over 500 people with AEE, the main food 
triggers were milk, egg, wheat, corn, beef, chicken, barley, oats, 
rice, and peanuts.
26 Although the majority of patients respond-
ed to elemental diets, only 11 patients experienced resolution 
of their AEE and eventually resumed an unrestricted diet with-
out medications. Since this is a mixed IgE and cell-mediated 
process, prick skin testing and serum specific IgE levels may not 
identify all the allergic triggers. Atopy patch testing has been in-
vestigated as an additional diagnostic tool to identify foods that 
cause delayed symptoms. 
MECHANISM OF FOOD ALLERGY
Normally, there is a delicate balance of the gastrointestinal 
mucosal immune system distinguishing between potentially 
harmful pathogens, beneficial commensal bacteria, and harm-
less food allergens which do not induce active immune re-
sponses. The mechanisms by which ingested proteins are able 
to interact with unique populations of antigen presenting cells 
leading to suppression of cellular and humoral immune re-
sponses has been termed oral tolerance. This has been demon-
strated in a murine model in which subcutaneous antigen ex-
posure resulted in cell-mediated and humoral responses to the 
antigen in vitro, but mice that were first orally exposed to the 
antigen then immunized subcutaneously had decreased im-
mune responses in vitro.
27 Transfer of T cells from the orally fed 
mice to naïve mice resulted in decreased immune responses as 
well. Different mechanisms of tolerance can occur depending 
on the dose of allergen exposure. Studies suggest that “high 
dose” tolerance is due to deletion of effector T cells, whereas 
“low dose” tolerance involves activation of regulatory T cells.
28
Loss of oral tolerance can occur or may be bypassed by anti-
gen presentation via alternative routes, such as through cutane-
ous exposures or via the respiratory tract. Using a murine model, 
epicutaneous or epidermal exposure to peanut was demon-
strated to induce Th2 immune responses and promoted aller-
gic sensitization.
29 In addition, higher rates of peanut allergy 
have been found in children with atopic dermatitis who used 
topical creams containing peanut oil (OR 6.8).
30 Respiratory ex-
posures are seen in pollen-food syndrome (PFS), an IgE-medi-
ated allergy that is due to cross-reacting proteins in pollens (the 
initial sensitizing allergen) and foods, which results in oropha-
ryngeal symptoms to raw fruits and vegetables.
31 
Breakdown of oral tolerance can also occur as a result of de-
fective regulatory T cells. The disorder of immune dysregula-
tion, polyendocrinopathy, enteropathy, X-linked (IPEX) syn-
drome is due to a mutation in the FOXP3 gene, a transcription 
factor on CD4+CD25+ regulatory T cells that has been implicat-
ed in blocking Th1 and Th2 responses. Atopic dermatitis and 
food allergies are known manifestations of this disorder.
32 The 
importance of T regulatory cells in tolerance was also demon-
strated in a study of non-IgE milk allergy. The development of 
tolerance to milk was associated with higher numbers of circu-
lating CD4+CD25+ regulatory T cells.
33
Host factors
Several host factors can influence the development of food al-
lergies. Different mouse strains are not equally susceptible to 
food allergies,
34,35 suggesting that genetic predisposition is im-
portant. Furthermore, the age of exposure to food allergens can 
determine whether tolerance or allergy develops. In a murine 
model, sensitization occurred when mice were orally fed oval-
bumin in the first week of life, however, tolerance was induced 
when the mice were orally exposed to ovalbumin at 2-3 weeks 
of age.
36 In humans, epidemiologic studies show a higher rate 
of food allergies in young children as compared to adults,
1 sug-
gesting that gut maturity may be a factor in the development of 
food allergies. On the other hand, population studies suggest 
that early introduction may be beneficial in some cases. In Isra-
el, where infants are fed peanut proteins starting at an early age, 
there is a lower incidence of peanut allergy as compared to the 
UK where peanut is not introduced to children until a much 
later age.
37 The Learning Early About Peanut Allergies (LEAP) 
study is currently exploring the role of timing of peanut allergen 
exposure in the development of peanut allergy.
Several studies suggest that disruption of normal gut barrier 
functions, such as gastric pH and commensal bacteria, can in-
crease the risk of food allergies. Gastric digestion normally 
serves to breakdown food proteins, and in many cases destroys 
immunogenic epitopes in the process. The role of gastric acidity 
was investigated by Untersmayr et al.
38 using a murine model. 
Mice fed caviar extract in combination with antacids had ele-
vated specific IgE and demonstrated immediate skin reactivity 
to the protein after immunization. However, mice which were 
not fed antacids did not demonstrate these immunologic re-
sponses, suggesting that use of antacid medications increased 
the risk of food allergen sensitization. In a human study of 152 
patients on antacid treatment for dyspepsia, increased food al-
lergen sensitization was seen in 25% after 3 months.
39 Gastric 
enzymes can affect allergenicity of food proteins. Specifically, 
the allergenicity of ovomucoid has been demonstrated to be re-
duced after gastric digestion.
40 Additionally, commensal bacte-
rial serve an important role. Mice raised in a germ-free environ-
ment do not develop normal tolerance,
41 and mice treated with 
antibiotics or those lacking in toll like receptor 4 (TLR4) are 
more easily sensitized to peanut than wild-type control mice.
42 
Additional host factors can modulate the clinical response of 
food allergy. For example, asthma has been shown to be a risk 
factor for more severe anaphylaxis. In a study of fatal food aller-Allergy Asthma Immunol Res. 2009 October;1(1):19-29.  doi: 10.4168/aair.2009.1.1.19
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gic reactions, the majority of victims had underlying asthma.
11 
Host factors such as exercise, use of medication (alcohol, aspi-
rin, beta-blockers, angiotensin converting enzyme inhibitors, 
monoamine oxidase inhibitors, tricyclic antidepressants), and 
concurrent infection may increase the severity of anaphylactic 
reactions or diminish the efficacy of epinephrine.
43,44 Recently, 
low serum platelet-activating factor acetylhydrolase (PAF-AH) 
activity has been found to be a risk factor for more severe food-
induced anaphylaxis.
45 
Food allergen factors 
Food allergies can produce an array of clinical symptoms. The 
presence of specific IgE to sequential or conformational epit-
opes can distinguish between different phenotypes of milk and 
egg allergy. Several studies show that binding of conformation-
al epitopes is associated with transient allergy to milk and egg 
whereas binding of sequential epitopes in these proteins is a 
marker for persistent allergy.
46,47 Recent studies demonstrate 
that the majority of milk and egg allergic individuals can toler-
ate extensively heated or baked forms of these foods,
15-18 indi-
cating that these individuals identify conformational epitopes 
that are disrupted by heating. Furthermore, studies show that 
different patterns of epitope recognition or epitope diversity 
may correlate with clinical manifestations of allergic reactions 
to peanut and milk.
48-51
Although heating appears to render many proteins less aller-
genic, heating does not have the same effect on all food pro-
teins. Roasting peanuts involves very high temperatures, and 
this causes a Maillard reaction leading to increased stability 
and allergenicity of peanut allergens.
52 This finding may explain 
the differences in prevalence of peanut allergy in the U.S. where 
peanuts are primarily consumed in the roasted form and China 
where boiled or fried peanuts predominate. 
Additional properties of peanut make it a highly allergenic 
protein. Glycosylated Ara h 1, a major peanut allergen, has 
been shown to act as a Th2 adjuvant by activating dendritic 
cells to drive Th2 cell maturation.
53 In contrast, deglycoslyated 
Ara h 1 did not activate dendritic cells. Recently, peanut pro-
teins were shown to have the ability to induce production of 
complement (C3a) leading to increased platelet-activating fac-
tor and histamine production by macrophages, basophils, and 
mast cells.
54
THERAPIES
Since no treatments are available to cure or provide long-term 
remission from food allergy, there is a strong need to develop 
effective therapies. Several strategies are currently being inves-
Table 2. Allergen-specific approaches for the treatment of food allergy 
Mechanism Effects Concerns Research status
Subcutaneous 
immunotherapy 
(SCIT)
Gradual exposure to allergens to 
induce desensitization or tolerance
Proven therapy for respiratory and 
venom allergy, equivocal results for 
oral allergy syndrome
High risk of anaphylaxis in peanut 
allergy studies
No current studies
Oral immunotherapy 
(OIT)
Gradual exposure to allergens to 
induce desensitization or tolerance
Improved clinical tolerance; studies 
mainly for milk and egg; recent 
double-blind, placebo-controlled 
study for milk
Unclear whether the effects are 
desensitization or induction of 
tolerance; side effects are common
Clinical
Sublingual immuno-
therapy (SLIT)
Gradual exposure to allergens to 
induce desensitization or tolerance
Improved clinical tolerance; largest 
study for hazelnut allergy
Unclear whether the effects are 
desensitization or induction of 
tolerance; side effects are common
Clinical
Recombinant 
vaccines
Mutate IgE binding sites; proteins 
stimulate T cells to proliferate, but 
have greatly reduced IgE-binding 
capacity 
Protection against peanut anaphy-
laxis in mice; study of Bet v 1 for 
OAS demonstrated improvement of 
symptoms
Improved safety profile compared 
with conventional IT, requires identi-
fication of IgE binding sites for each 
allergen
Preclinical and 
clinical
Peptide immuno-
therapy
Peptide fragments contain T cell 
epitopes, but are not of sufficient 
length to cross-link IgE and there-
fore, cannot trigger mast cell or 
basophil activation;
Protection against peanut anaphy-
laxis in mice
Improved safety profile compared 
with conventional IT, requires identi-
fication of T cell epitopes for each 
allergen
Preclinical
ISS-conjugated 
protein immuno-
therapy
ISS bound to proteins can act as 
adjuvants to promote switching to a 
Th1 response
Protection against peanut sensitiza-
tion in mice
Concern for excessive Th1 stimula-
tion, and potential for autoimmunity
Preclinical
Plasmid DNA 
immunotherapy
Allergen gene immunization to 
promote endogenous allergen 
production resulting in possible 
induction of tolerance
Less severe and delayed peanut-
induced anaphylaxis in a murine 
model
Serious concerns regarding safety 
in view of strain-dependent effects 
in mice
PreclinicalAllergy Asthma Immunol Res. 2009 October;1(1):19-29.  doi: 10.4168/aair.2009.1.1.19
Advances in food allergy AAIR 
23 http://e-aair.org
tigated, both allergen-specific (Table 2) and allergen non-spe-
cific (Table 3). Allergen-specific approaches attempt to alter the 
allergic response to specific food allergens, whereas allergen 
non-specific treatments are aimed at modulating the overall al-
lergic response. These non-specific approaches would be par-
ticularly beneficial for individuals suffering from multiple food 
allergies. 
Allergen specific therapies
Allergen Immunotherapy
Immunotherapy entails gradual exposure to allergens in the 
hope of desensitization (temporary loss of responsiveness due 
to continuous exposure) and/or promoting tolerance (perma-
nent immunologic nonresponse). Although widely used for re-
spiratory allergies, the mechanisms of immunotherapy are not 
well understood, but is believed to involve initial desensitiza-
tion of mast cells and basophils, changes in allergen-specific T 
cell responses and/or induction of regulatory T cells and late 
effects on effector cells, including eosinophils and B cells.
55 
Food specific immunotherapy has been investigated as a po-
tential treatment for food allergy. 
Subcutaneous immunotherapy (SCIT) has been used since 
1911, and is highly efficacious for allergic rhinitis, asthma and 
insect sting allergy.
56,57 However, early attempts at using SCIT 
for food allergies demonstrated unacceptably high rates of se-
vere adverse reactions.
58,59 Since pollen-food syndrome (PFS) 
occurs due to cross-reactivity with pollens, SCIT would seem to 
be a logical treatment for PFS as well. Although results demon-
strate clinical improvements in many patients, these studies 
lacked appropriate control groups and relied on self-reported 
symptoms.
60,61 Furthermore, with difficulties in objective evalu-
ations for improvement in symptoms in PFS and lack of con-
sensus for target doses, SCIT remains an unproven therapeutic 
approach for PFS.
Given the high rates of adverse reactions with SCIT, alterna-
tive routes of administering immunotherapy are being investi-
gated to improve the risk-benefit ratio. There is an expanding 
body of literature that reports a high rate of efficacy with oral 
immunotherapy (OIT) (75-86%) with various food allergens.
62 
The first double-blind, placebo-controlled OIT study for food 
allergy in children was performed by Skripak et al.
63 for milk al-
lergy. Twelve patients completed 3-4 months of active treat-
ment. Although no significant changes in specific IgE levels or 
skin prick test results were observed, there was a significant in-
crease in milk-specific IgG and IgG4 in the active group. More 
importantly, the majority of participants experienced reactions 
during the post-OIT food challenge, demonstrating that com-
plete protection from allergic reactions due to milk was not 
achieved. Furthermore, all participants continued daily intake 
of dairy, therefore, it is unclear whether any OIT participants 
developed tolerance rather than desensitization to milk. 
Additional studies have investigated the effects and safety of 
OIT in varying patient populations and using different dosing 
regimens. Longo et al.
64 reported on their experience with OIT 
in a highly milk allergic population. After 1 yr, 36% of the OIT 
group had unrestricted diets, and more than half (54%) were 
able to tolerate limited amounts of milk (ranging from 5-150 
mL). Adverse reactions were common and occurred in all chil-
dren on OIT. This study demonstrated that OIT can be effective 
even for those with the most severe allergies. The authors noted 
that although adverse events were common, in cases of persis-
tent milk allergy and a high risk of accidental exposures and re-
actions, the risks of treatment may be acceptable. Staden et al.
65 
reported a case series of 9 high-risk children who successfully 
underwent a rush oral immunotherapy protocol with milk, 
suggesting that desensitization can be achieved quickly. Ad-
verse effects were frequent, but generally mild.
Recently, Jones et al.
66 reported an open-label peanut oral im-
munotherapy (OIT) study in which desensitization was suc-
cessful in 93% of patients. The authors assessed several immu-
Table 3. Allergen non-specific approaches for the treatment of food allergy
Mechanism Effects Concerns Research status
Anti-IgE Decreases circulating free IgE, inhibits the 
early and late phase allergic response, 
suppresses inflammation and provides 
improved control for allergic diseases 
Provided an improved threshold 
against peanut-induced reactions in 
80% of treated patients
May be useful in combina-
tion with immunotherapy
Clinical 
Chinese herbal 
medicine
Inhibit Th2 immune response Long-term protection from peanut 
anaphylaxis in a murine model. Also 
effective in murine model of multiple 
food allergies
Oral, generally safe and 
well tolerated; currently in 
Phase I trial
Clinical
Cytokine/anti-cytokine  Block pro-allergic cytokines Clinical improvement in patients with 
eosinophilic esophagitis (IL-5)
Concerns for systemic side 
effects
Clinical
TLR-9 Induction of Th1-type immune responses Protect from peanut anaphylaxis in a 
murine model
Concern for excessive Th1 
stimulation, and potential 
for autoimmunity
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nological parameters and presented several interesting results 
about possible mechanisms of OIT. Declines in skin prick tests 
and peanut-specific IgE levels and increases in peanut-specific 
IgG4 were observed. A significant decrease in basophil activa-
tion was detected, as well as increases in several cytokines, in-
cluding IL-10 and IL-5, which suggests that OIT does not cause 
the typical downregulation of Th2 and upregulation of Th1 pro-
files. In addition, T-cell microarrays demonstrated downregula-
tion of apoptotic genes, indicating a potential role for apoptosis 
in OIT. 
Sublingual immunotherapy (SLIT), which has been demon-
strated to be a safe and effective treatment for allergic rhinitis 
and asthma, is another attractive option for the treatment of 
food allergy. Enrique et al.
67 published a randomized double-
blind, placebo-controlled study investigating SLIT for hazelnut 
allergy. Twelve patients with hazelnut allergy (6 with PFS) were 
treated with SLIT for 5 months using the sublingual-discharge 
technique. Significant increases in threshold of sensitivity to 
hazelnut were observed following treatment. There was also an 
increase in hazelnut-specific IgG4 and IL-10 after treatment in 
the active group. Local reactions occurred in 7.4% and systemic 
reactions were low (0.2%). A follow-up report of 7 patients from 
the active treatment group who resumed SLIT 4 months after 
discontinuation demonstrated tolerance of significantly in-
creased doses of hazelnut, decreased specific IgE, and in-
creased specific IgG4, thus demonstrating the beneficial effect 
of SLIT even after treatment interruption.
68 A recent random-
ized, double-blind, placebo-controlled clinical trial of SLIT for 
peach allergy also reported promising results of improved aller-
gen tolerance that was associated with decreases in skin test re-
activity and significant increases in IgE and IgG4 to Pru p 3.
69
One multicenter study investigated the effects of birch pollen 
SLIT for PFS.
70 Twenty patients with pollen-associated apple al-
lergy received 1 yr of SLIT. Although improvement in nasal 
provocation scores to birch pollen was seen in 9 patients, there 
was no significant improvement in their apple-induced oral 
symptoms. In addition, there was no change in specific IgE or 
IgG4 to the major apple allergen, Mal d 1, after treatment. The 
authors concluded that SLIT with birch pollen may have no 
clinical effect on associated apple allergy. 
Overall, immunotherapy appears to be a promising option for 
the treatment of food allergy, especially as safer routes of ad-
ministration are being investigated. Additional randomized, 
placebo-controlled trials are necessary to determine the true 
efficacy and safety of this method and to standardize extracts, 
protocols and durations of treatment. Furthermore, studies are 
needed to clarify whether these clinical improvements are due 
to true induction of oral tolerance or desensitization and to gain 
insight into the mechanisms of these treatments. 
Modified recombinant vaccines 
Modified recombinant food proteins are engineered to de-
crease IgE binding capacity while retaining the protein’s ability 
to stimulate T cell in order to decrease adverse effects of immu-
notherapy due to allergen activation of mast cells and baso-
phils. Currently, recombinant peanut,
71,72 apple
73 and fish
74 al-
lergens have been generated. Modified peanut allergens (Ara h 
1, 2, 3), altered using site-directed mutagenesis, can stimulate T 
cells from peanut allergic individuals to proliferate, but have 
greatly reduced IgE-binding capacity as compared to wild-type 
peanut protein.
71,72 Heat-killed E. coli (HKE) producing recom-
binant peanut proteins have been shown to have protective ef-
fects in a murine model of peanut anaphylaxis.
75 Peanut-sensi-
tized mice treated with HKE containing modified proteins Ara h 
1-3 (HKE-MP123) demonstrated reduced symptom scores dur-
ing peanut challenge as compared to the placebo-treated 
group. This protection lasted up to 10 weeks post-treatment in 
the medium and high dose treated groups. The high-dose treat-
ed group demonstrated the most significant decrease in IgE 
levels and decreased production of IL-4, IL-5, IL-13 and IL-10, 
and increased IFN-g and TGF-b production by splenocytes. The 
mechanisms are hypothesized to involve Th1 cytokines and/or 
T regulatory cells suppressing Th2 cell activation and mast cell/
basophil mediator release on re-exposure to antigen.
76,77 Clini-
cal trials are planned. 
SCIT with modified birch pollen allergens (Bet v 1 fragments, 
Bet v 1 trimer) has been shown to be moderately effective for 
patients with PFS.
78 Seven, out of 25 patients on active treat-
ment, reported improvement in their oral symptoms as com-
pared to only 1 of 19 placebo-treated patients. 
Peptide immunotherapy 
Use of peptide fragments that contain T cell epitopes that are 
not of sufficient length to cross-link IgE, is another potential 
strategy to decrease adverse effects of immunotherapy related 
to mast cell or basophil activation. A preliminary in vitro study 
using pepsin-digested peanut peptides showed induction of 
IFN-g (Th1 cytokine) from peripheral blood mononuclear cells 
in a concentration-dependent manner.
79 In a murine model of 
peanut allergy, mice receiving immunotherapy with peptides 
containing IgE epitopes to the major peanut protein Ara h 2 
prior to allergen challenge experienced only mild allergic reac-
tions as compared to sham-treated mice, which exhibited se-
vere anaphylactic reactions.
80 Although these preliminary mu-
rine studies are promising, validating the stability and unifor-
mity of peptide mixtures for human use poses a significant 
challenge. 
Immunostimulatory sequence-conjugated protein  
immunotherapy
Immunostimulatory sequences (ISS), such as CpG oligode-
oxynucleotides, bound to proteins can act as adjuvants to pro-
mote switching to a Th1 response,
81 thus making the proteins 
less allergenic. Early studies using ragweed allergen showed Allergy Asthma Immunol Res. 2009 October;1(1):19-29.  doi: 10.4168/aair.2009.1.1.19
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that immunotherapy with ISS in combination with Amb a 1, 
the major ragweed allergen, promoted Th1 responses and re-
duced allergenicity in mice, rabbit and primates.
82 The mice 
then underwent a sensitization protocol to beta-gal. Similarly, 
mice immunized with beta-galactosidase plus an ISS sequence 
oligodeoxynucleotide were protected from developing fatal 
anaphylaxis and had lower plasma histamine levels after aller-
gen challenge compared to the group treated with beta-gal pro-
tein alone.
83 
A similar approach was investigated in a murine model of 
peanut-induced anaphylaxis.
84 Mice treated with ISS-linked Ara 
h 2 (a major peanut protein) had lower symptoms scores and 
lower plasma histamine levels following challenge with Ara h 2 
compared to the mice treated with ISS-linked Amb a 1. A signif-
icantly higher Ara h 2-specific IgG2a levels in the ISS-linked Ara 
h 2 treated mice was seen, but there was no significant differ-
ence in specific-IgE or IgG1 levels between the two groups. 
These findings suggest that ISS-conjugated protein immuno-
therapy may be an effective treatment for food allergy. 
 
Plasmid DNA immunotherapy
Allergen gene immunization is another approach to immu-
nomodulate the allergic response. DNA nanoparticles contain-
ing the gene for Ara h 2 was synthesized by complexing plasmid 
DNA with chitosan and then administered these nanoparticles 
orally to mice.
85 Immunized mice demonstrated less severe and 
delayed anaphylactic responses following challenge compared 
to mice treated with ‘naked’ DNA or unimmunized mice, and 
this was associated with decreased IgE levels, lower plasma his-
tamine, and less vascular leakage. Despite promising results in 
the murine model, concerns regarding use in humans are a po-
tential disadvantage of this technique. 
Allergen non-specific therapies
Anti-IgE
Approved for the treatment of asthma with associated envi-
ronmental allergies, recombinant monoclonal humanized anti-
IgE treatment causes decreased circulating free IgE, inhibits the 
early and late phase allergic response, suppresses inflamma-
tion and provides improved control for allergic diseases.
86 A 
double-blind, randomized, dose-ranging trial in 84 patients 
with a history of peanut allergy was the first investigation of this 
for the management of food allergy.
87 Patients were random-
ized to receive either TNX-901 (150, 300, or 450 mg of anti-IgE 
antibodies) or placebo for 4 months. Patients receiving the 
highest dose experienced significant decreases in symptoms 
with peanut challenge as compared to the placebo group. The 
median threshold of sensitivity to peanut increased from 178 
mg peanut protein (the equivalent to one peanut) to almost 9 
peanuts (2.8 grams). Although 25% of patients were able to tol-
erate over 20 peanuts post-treatment, another 25% failed to de-
velop any change in tolerance to peanut indicating that the 
treatment response can be variable. Investigation of another 
anti-IgE preparation, omalizumab (Xolair
®, Genentech), for the 
treatment of peanut allergy was initiated, but discontinued for 
safety issues related to the protocol.
88
Combination therapy of anti-IgE and allergen immunothera-
py is being investigated as a method to decrease adverse reac-
tions to immunotherapy in order to allow increased safety and 
efficacy.
89 No data is currently available regarding the effective-
ness of this strategy.
Chinese herbal medicine
A 9-herb formula based on Traditional Chinese Medicine is 
currently under investigation as a treatment of food allergy. It is 
named the food allergy herbal formula (FAHF-2) and is effec-
tive in a murine model of peanut-induced anaphylaxis.
90 Pea-
nut-allergic mice treated with FAHF-2 had no signs of anaphy-
laxis after peanut challenge, but all sham-treated mice had se-
vere symptoms of anaphylaxis, decreased rectal temperatures, 
elevated plasma histamine, and marked vascular leakage. 
There were also associated decreases in peanut-specific IgE 
levels and Th2 cytokine production (IL-4, IL-5, IL-13). The pro-
tective effects of FAHF-2 were demonstrated to last up to 6 
months post-therapy, which represents about 25% of the life-
span of the mouse.
91 Furthermore, these effects are not peanut-
specific; treatment has been shown to modulate the allergic re-
sponse in a murine model of multiple food allergies.
92
Peliminary studies with purified human peripheral blood 
mononuclear cells from peanut-allergic individuals showed 
that cells stimulated with crude peanut extract in the presence 
of FAHF-2 had a decrease in antigen-dependent T-cell prolifer-
ation. A dose-dependent decrease in Th2 cytokine production 
(IL-5 and IL-13) and increase in IFN-g production were also 
seen, indicating that FAHF-2 specifically inhibits the Th2 re-
sponse.
93 Recently, the U.S. FDA approved a botanical drug IND 
for FAHF-2 and a Phase I trial is currently underway. 
Cytokine/Anti-cytokine
Allergic diseases develop in part because of imbalances in T 
helper (Th) type 1 and type 2 cytokines. Strategies to block pro-
allergic cytokines have been investigated as potential therapeu-
tic approaches. Use for management of allergic asthma has 
been most widely investigated, however, applications in the 
field of food allergies are emerging. 
Eosinophilic esophagitis (EE) is a inflammatory disorder 
characterized by high numbers of intraepithelial eosinophils in 
the esophagus.
23-25 Data from murine models of EE and analysis 
of human esophageal tissue demonstrate the presence of T 
cells and mast cells along with eosinophils, indicating that a 
Th2-based inflammatory process is a key feature of EE.
94,95 Since 
IL-5, a major Th2 cytokine, is a regulator of eosinophil function 
and survival, anti-IL-5 (mepolizumab) has been investigated as 
a treatment for EE.
96 Promising results were seen in an open-la-Allergy Asthma Immunol Res. 2009 October;1(1):19-29.  doi: 10.4168/aair.2009.1.1.19
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bel phase I/II study of anti-IL-5 in 4 adults with EE. Decreases 
in peripheral and esophageal eosinophilia and symptomatic 
improvement were seen after 3 monthly infusions of anti-IL-5 
(750 mg intravenously). 
Recombinant IL-12 has also been investigated for the treat-
ment of allergic disorders because IL-12 promotes the develop-
ment of Th1 effector cells and inhibits Th2 class switching. Ben-
eficial effects of reducing blood and sputum eosinophil num-
bers in asthmatic patients have been seen, however, significant 
systemic toxicities pose a significant barrier to use.
97 A less toxic 
route of intranasal administration of IL-12 using the nonpatho-
genic lactic acid bacteria (Lactococcus lactis) as a vehicle has 
been investigated in a murine model. Pretreatment of mice 
with L. lactis strains expressing bovine-lactoglobulin (BLG) 
with an IL-12-producing L. lactis protected sensitized mice 
against intranasal challenge with BLG antigen.
98
 
Toll-like receptors 
Since stimulation of toll-like receptor 9 (TLR9) can lead to 
strong mucosal and systemic Th1-type immune responses, the 
effects of a synthetic TLR9 agonist has been investigated in a 
murine model of food allergy.
99 After oral administration, de-
creased gastrointestinal inflammation and protection from 
peanut-induced anaphylaxis was observed during or after pea-
nut sensitization. Decreases in IgE and increases in IgG2a levels 
were also detected. The authors postulated that these effects 
were due to TLR9 agonist induction of Th1-type immune re-
sponses. 
Additional strategies currently being investigated for other   
allergic disorders 
A novel human immunoglobulin Fc-Fc fusion protein, cross-
linking the high-affinity FcRI and low-affinity FcRIIb on mast 
cells and basophils leading to inhibition of degranulation, has 
been developed.
100 The same group has also developed a hu-
man gamma-allergen fusion protein to achieve the same inhi-
bition in an allergen-specific manner.
101 The Fc-Fel d 1 fusion 
protein inhibited Fel d 1-mediated degranulation in purified 
human basophils from cat allergic patients and blocked the al-
lergic responses in a mouse model. Since many food allergens 
are already well-characterized, a similar approach can be taken 
for food allergy.
CONCLUSIONS
We are continuing to gain more insight into the immune 
mechanisms leading to the loss of oral tolerance and develop-
ment of food allergies. A complex combination of host factors 
and food allergen properties interact to determine whether tol-
erance or allergy develops in a given individual. With increased 
knowledge of these various factors, potential treatments can be 
developed. Currently, a variety of promising therapeutic strate-
gies are being investigated. These, either alone or in combina-
tion, will hopefully provide long-term treatment options and 
potentially a cure for food allergy.
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